KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Asset Writedowns and Impairment: 2009-2025

  • Novavax's Asset Writedowns and Impairment was N/A to $97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.8 million, marking a year-over-year change of. This contributed to the annual value of $4.1 million for FY2024, which is 59.01% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Asset Writedowns and Impairment is $97.0 million, which was up 27,704.58% from $349,000 recorded in Q2 2025.
  • In the past 5 years, Novavax's Asset Writedowns and Impairment registered a high of $97.0 million during Q3 2025, and its lowest value of -$155.7 million during Q2 2022.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $1.7 million (2024), whereas its average is $21.6 million.
  • Data for Novavax's Asset Writedowns and Impairment shows a peak YoY skyrocketed of 106.49% (in 2023) over the last 5 years.
  • Novavax's Asset Writedowns and Impairment (Quarterly) stood at -$155.7 million in 2022, then spiked by 106.49% to $10.1 million in 2023, then reached -$1.3 million in 2024, then reached $97.0 million in 2025.
  • Its Asset Writedowns and Impairment stands at $97.0 million for Q3 2025, versus $349,000 for Q2 2025 and -$1.3 million for Q4 2024.